Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards granted to a new employee under its 2019 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The awards, effective January 13, 2025, include:
1. A non-statutory stock option to purchase 95,600 shares at market price, vesting over four years with 25% vesting on January 13, 2026, and the remainder monthly over three years.
2. A restricted stock unit award for 31,375 shares, vesting in equal annual installments over three years, starting January 13, 2026.
Both awards are contingent on continued employment with Ocular through the vesting dates.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato premi di indennità concessi a un nuovo dipendente nell'ambito del suo Piano di Incentivazione azionaria del 2019, in conformità con la Regola di quotazione 5635(c)(4) di Nasdaq. I premi, con effetto dal 13 gennaio 2025, includono:
1. Un'opzione su azioni non statutarie per acquistare 95.600 azioni al prezzo di mercato, con un periodo di maturazione di quattro anni, con il 25% che matura il 13 gennaio 2026 e il resto mensilmente per tre anni.
2. Un premio in azioni riservate di 31.375 azioni, con maturazione in rate annuali uguali per tre anni, a partire dal 13 gennaio 2026.
Entrambi i premi sono subordinati al mantenimento dell'impiego con Ocular fino alle date di maturazione.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado premios de incentivo otorgados a un nuevo empleado bajo su Plan de Incentivación de Acciones de 2019, en cumplimiento con la Regla de Cotización 5635(c)(4) de Nasdaq. Los premios, efectivos a partir del 13 de enero de 2025, incluyen:
1. Una opción de acciones no estatutaria para comprar 95,600 acciones al precio de mercado, que se adquirirán durante cuatro años con un 25% que se adquirirá el 13 de enero de 2026, y el resto mensualmente durante tres años.
2. Un premio de unidad de acciones restringidas de 31,375 acciones, que se adquirirá en cuotas anuales iguales durante tres años, comenzando el 13 de enero de 2026.
Ambos premios están supeditados a la continuación del empleo con Ocular hasta las fechas de adquisición.
Ocular Therapeutix (NASDAQ: OCUL)는 2019년 유인 주식 인센티브 계획에 따라 새로운 직원에게 부여된 유인 보상을 발표했습니다. 이는 나스닥 상장 규칙 5635(c)(4)를 준수하는 것입니다. 이 보상은 2025년 1월 13일부터 효력이 발생하며, 포함 사항은 다음과 같습니다:
1. 시장 가격으로 95,600주를 구매할 수 있는 비법적 주식 옵션으로, 4년 동안 25%가 2026년 1월 13일에 배정되고 나머지는 매달 3년간 배정됩니다.
2. 31,375주에 대한 제한 주식 단위 보상으로, 2026년 1월 13일부터 시작하여 3년간 동일한 연간 할부로 배정됩니다.
두 보상은 배정일까지 Ocular에서 계속 근무하는 것을 조건으로 합니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé des récompenses d'incitation accordées à un nouvel employé dans le cadre de son Plan d'Incentive d'Actions de 2019, en conformité avec la Règle de cotation 5635(c)(4) du Nasdaq. Les récompenses, effectives à partir du 13 janvier 2025, comprennent :
1. Une option d'achat d'actions non statutaire pour acheter 95 600 actions au prix du marché, acquérant par tranche de 25 % le 13 janvier 2026, et le reste mensuellement pendant trois ans.
2. Une récompense d'unités d'actions restreintes pour 31 375 actions, acquérant par tranches annuelles égales pendant trois ans, à compter du 13 janvier 2026.
Les deux récompenses sont conditionnées à la continuation de l'emploi avec Ocular jusqu'aux dates d'acquisition.
Ocular Therapeutix (NASDAQ: OCUL) hat Anreize für einen neuen Mitarbeiter nach seinem Anreizaktienplan von 2019 angekündigt, in Übereinstimmung mit der Nasdaq-Notierungsregel 5635(c)(4). Die Awards, die am 13. Januar 2025 wirksam werden, umfassen:
1. Eine nicht-statuarische Aktienoption zum Kauf von 95.600 Aktien zum Marktpreis, die über vier Jahre vestausgezeichnet wird, wobei 25 % am 13. Januar 2026 und der Rest monatlich über drei Jahre fällig wird.
2. Eine Auszeichnung in Form von eingeschränkten Aktieneinheiten für 31.375 Aktien, die in gleichen jährlichen Raten über drei Jahre ab dem 13. Januar 2026 vestausgezeichnet wird.
Beide Auszeichnungen sind an eine fortdauernde Beschäftigung bei Ocular bis zu den Vestingterminen geknüpft.
- None.
- None.
BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted effective as of January 13, 2025 and consist of (i) a non-statutory stock option to purchase up to 95,600 shares of Ocular’s common stock at a per share exercise price equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant, and (ii) a restricted stock unit award representing the right to receive 31,375 shares of Ocular’s common stock. The stock option has a ten-year term and is scheduled to vest over four years, with
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What are the details of OCUL's January 2025 inducement stock options grant?
How many restricted stock units (RSUs) did OCUL grant in January 2025?
What is the vesting schedule for OCUL's January 2025 inducement awards?
Under which plan were OCUL's January 2025 inducement awards granted?
